Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jesse L. Coy"'
Autor:
Patrick A. Flynn, Mark D. Long, Yoko Kosaka, Nicola Long, Jessica S. Mulkey, Jesse L. Coy, Anupriya Agarwal, Evan F. Lind
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Dendritic cells (DC) are mediators between innate and adaptive immune responses to pathogens and tumors. DC development is determined by signaling through the receptor tyrosine kinase Fms-like tyrosine kinase 3 (FLT3) in bone marrow myeloid progenito
Externí odkaz:
https://doaj.org/article/3e30080c310749e18369d64f85070101
Autor:
Kyle A. Romine, Kevin MacPherson, Hyun-jun Cho, Yoko Kosaka, Patrick A. Flynn, Kaelan H. Byrd, Jesse L. Coy, Matthew T. Newman, Ravina Pandita, Christopher P. Loo, Jaime Scott, Andrew C. Adey, Evan F. Lind
Publikováno v:
Leukemia. 37:580-592
Many acute myeloid leukemia (AML) patients exhibit hallmarks of immune exhaustion, such as increased myeloid-derived suppressor cells, suppressive regulatory T cells and dysfunctional T cells. Similarly, we have identified the same immune-related fea
Autor:
Matthew T. Newman, Jaime Scott, Evan F. Lind, Jesse L. Coy, Hyun-jun Cho, Kaelan Byrd, Christopher P. Loo, Kyle A. Romine, Patrick A. Flynn, Yoko Kosaka
Many acute myeloid leukemia (AML) patients exhibit hallmarks of immune exhaustion, such as increased myeloid derived suppressor cells (MDSCs), suppressive regulatory T cells (Tregs) and dysfunctional T cells. We have developed a mouse model of AML dr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94e20a348eca2dc8dca0a80900b7efe7
https://doi.org/10.1101/2021.08.04.455147
https://doi.org/10.1101/2021.08.04.455147
Autor:
Yoko Kosaka, Matthew T. Newman, Kyle A. Romine, Patrick J. Flynn, Jesse L. Coy, Evan F. Lind, Christopher P. Loo, Kaelan Byrd, Hyun-jun Cho
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundAcute Myeloid Leukemia (AML) is the most common adult leukemia and has a very poor prognosis. With a 5-year survival of under 30% (seer.cancer.gov), most people diagnosed with AML will die from the disease. AML is caused by an uncontrolled
Publikováno v:
The Journal of Immunology. 208:61.17-61.17
Acute myeloid leukemia (AML) is a hematological cancer with a very poor prognosis. FLT3-ITD mutations that cause constitutive FLT3 signaling are commonly seen in patients. Our lab and others have shown that AML patient samples exhibit hallmarks of im
Autor:
Kyle Alexander Romine, Hyun-jun Cho, Yoko Kosaka, Patrick Flynn, Kaelan H Byrd, Jesse L Coy, Matthew T Newman, Jaime Scott, Christopher Loo, Evan F Lind
Publikováno v:
The Journal of Immunology. 208:122.15-122.15
Acute Myeloid Leukemia (AML) is the most common adult leukemia and has a 5-year survival of under 30%. AML is caused by uncontrolled proliferation of myeloid cells resulting from a combination of mutations that affect proliferation, differentiation a